Skip Navigation


NDT Advance Access originally published online on December 8, 2007
Nephrology Dialysis Transplantation 2008 23(2):431-433; doi:10.1093/ndt/gfm865
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrowOA All Versions of this Article:
23/2/431    most recent
gfm865v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in NDT
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Steinman, T. I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Steinman, T. I.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2007].
The online version of this article has been published under an open access model. Users are entitled to use, reproduce, disseminate, or display the open access version of this article for non-commercial purposes provided that: the original authorship is properly and fully attributed; the Journal and Oxford University Press are attributed as the original place of publication with the correct citation details given; if an article is subsequently reproduced or disseminated not in its entirety but only in part or as a derivative work this must be clearly indicated. For commercial re-use, please contact journals.permissions@oxfordjournals.org


Renal and cardiac effects of antihypertensive treatment with ramipril versus metoprolol in autosomal dominant polycystic kidney disease

Theodore I. Steinman

Renal Division, Beth Israel Deaconess Medical Center, Harvard Medical School, MA, USA

Correspondence and offprint requests to: Theodore I. Steinman, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Avenue ST 220, Boston, MA 02215, USA. Tel: +1-617-667-5278; Fax: +1-617-975-5595; E-mail: tsteinma@bidmc.harvard.edu

Keywords: polycystic kidney disease; hypertension; ACE inhibitors versus beta blockers

The first 10% of the full text of this article appears below.

Autosomal dominant polycystic kidney disease (ADPKD) affects ~12.5 million people worldwide. Forty percent of patients are diagnosed by 45 years of age. ADPKD is the fourth most common cause for end-stage renal disease (ESRD) worldwide and this disease accounts for 5–10% of renal transplant recipients [1,2]. Therefore, any therapeutic modality that can slow down the natural course history of this disease would have a significant impact on patients’ well-being and would be financially cost-effective. The manuscript by Zeltner et al. in this issue attempts to determine if there is a difference between an angiotensin-converting enzyme (ACE) inhibitor (ramipril) and a beta blocker (metoprolol) when employing first-line therapy in ADPKD patients with hypertension.

The study has a number of limitations; some of them recognized by the authors that could influence the . . . [Full Text of this Article]

Clinical trials to slow progression of ADPKD
Activation of the RAAS in ADPKD

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in NDT:

Renal and cardiac effects of antihypertensive treatment with ramipril vs metoprolol in autosomal dominant polycystic kidney disease
Raoul Zeltner, Roudolf Poliak, Birgit Stiasny, Roland E. Schmieder, and Bernd D. Schulze
NDT 2008 23: 573-579. [Abstract] [FREE Full Text]  

In this issue ...

NDT 2008 23: i. [Extract] [FREE Full Text]